Replies to post #24119 on Marker Therapeutics Inc (MRKR)

[Maciste]

dyp,

I remember you stating that at some point you would want back in. At what levels are you a buyer?

[seamirafly]

Kite Pharma, Inc. (NASDAQ:KITE), a clinical-stage biopharmaceutical firm pursuing novel cancer immunotherapy products, plans to raise $78.0 million in its upcoming IPO.

The Santa Monica, California-based firm will offer 6.0 million shares at an expected price range of $12-$14 per share. If the IPO can find the midpoint of that range, at $13 per share, KITE will command a market value of $548 million.

Kite was a clinical stage biopharmaceutical without a product and ended up at $17 a share on the day of its IPO. And we know the rest of the story. We offer a far superior product. So why do you think our share price is so overvalued? Am I missing something here?

[dyp]

$6.84
that should perk up
some of the chartists
in the crowd.